Brain Tumor Diagnosis And Treatments Market Report

Market Insights

The brain tumor diagnosis and treatments market is projected to grow from USD 289.88 billion in 2022 to USD 476.86 billion by 2028 at a CAGR of 8.60% during the forecast period.

 Wish to get a Free Sample? Register Here.

What is a brain tumor?

A brain tumor is an uncontrolled and abnormal proliferation of cells in the brain. It can be benign or malignant. The brain tumor arises and hardly spreads from the brain tissue. The tumor then compresses other structures in the brain and destroys them. Brain tumors primarily occur in supportive brain tissues. The main cause of brain tumors is not yet known, and it can occur at any age.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately affected the brain tumor diagnosis and treatment industry. The rapid spread of COVID-19 has led to several thousands of hospital admissions. The focus of healthcare professionals has been shifted toward the treatment of COVID-19-infected patients, which affected the treatment of non-emergency medical conditions, amid the pandemic.

Market Drivers

The market is driven by a host of factors, some of which are noted below:

• An increasing number of patients suffering from neurological disorders around the world.
• The growing prevalence of the geriatric population & surging number of smokers.
• Rising government initiatives regarding growing awareness of advanced technologies.
• Growing demand for diagnosis and treatment of brain tumors.
• Favorable reimbursement policies are some of the key factors expected to augment the market.

Brain Tumor Diagnosis and Treatments Market: Trends and Opportunities

• Rising incidence of brain tumors: Brain tumors have become more common as a result of a variety of variables such as increased age, environmental exposure, and genetic predisposition. This is projected to propel the brain tumor diagnosis and treatment market forward.
• Advancements in diagnostic technologies: Technologies for diagnosing brain tumors, such as magnetic resonance imaging (MRI), positron emission tomography (PET), and single-photon emission computed tomography (SPECT), have undergone major developments. The ability to detect brain tumors early thanks to these developments is crucial for bettering patient outcomes.
• Development of new treatment options: Recent years have seen the development of several new therapies for brain tumors, including targeted therapy, immunotherapy, and gene therapy. The results of patients are being improved as a result of these novel treatment alternatives, which are more efficient than conventional treatments like surgery and radiation therapy.
• Increased focus on personalized medicine: There is a rising emphasis on personalized medicine for brain tumors, which involves adapting treatment to the specific tumor profile of each patient. This is made possible by breakthroughs in molecular profiling, which enables the identification of specific genetic alterations that drive tumor growth.
• Growing demand for minimally invasive treatments: Minimally invasive treatments for brain tumors, such as stereotactic radiosurgery and minimally invasive surgery, are in high demand. Traditional treatments are connected with a decreased risk of problems and a shorter recovery period.

To Get the full scope of the report, Register Here.

Emerging Technologies that Could Impact the Future of Brain Tumor Diagnosis and Treatment:

• The increasing use of artificial intelligence (AI) in the diagnosis and treatment of brain tumors: AI is being utilized to create new diagnostic tools and increase treatment planning accuracy. AI-powered image analysis techniques, for example, can be used to identify brain tumors more precisely than traditional methods.
• The development of new delivery methods for cancer drugs: New cancer medicine delivery systems are being developed in order to more efficiently target tumors and reduce treatment adverse effects. Nanoparticles, for example, are being created to deliver cancer treatments directly to tumors.
• The increasing use of clinical trials to evaluate new treatments for brain tumors: Clinical trials are being utilized to assess the safety and efficacy of new brain tumor treatments. This is assisting in the discovery of new and improved treatments for patients with brain tumors.

Segment Analysis

Type

The market has been classified into primary brain tumors & secondary brain tumors. Under these, the primary brain tumors segment dominated the market with the highest share in 2022 & is expected to grow at a fast pace during the forecast period. The primary brain tumor can be further bifurcated into common tumors such as meningioma, astrocytomas, gliomas, and pituitary tumors. 

Meningioma remains the most common cancer throughout the world, including Asia Pacific and Europe. CNS and brain tumors are the third most prevalent malignancy among young adults and juveniles in these two locations, accounting for the majority of cancer-related deaths in this age group

End-Use Trends

The market has been classified into hospitals and medical centers. Under these, the hospital segment held the largest market share in 2022 and is likely to grow at a considered CAGR during the forecast period.

Hospitals are the first place where the brain tumor is tested and diagnosed. Well-equipped infrastructure and facilities with qualified healthcare professionals further bolster the segment's growth.

Regional insight

North America held a significant share of the market in 2022 and is projected to grow at a healthy CAGR during the forecast period.

Want to know which region offers the best growth opportunities? Register Here.

Rising healthcare spending, strong presence of key players, extensive research and development activities, a large volume of people diagnosed with a brain tumor, increasing healthcare awareness regarding the treatment & management of brain tumors, well-established healthcare infrastructure, and favorable reimbursement & insurance plans, augments the regional market growth during the forecast timeline.

Segmentation

This report studies the market covering a period of 12 years of trend and forecast. The report provides detailed insights into the market dynamics to enable informed business decision-making and growth strategy formulation based on the opportunities present in the market.

The market is segmented into the following categories:

By Type

• Primary Brain Tumor
• Secondary Brain Tumor

By End-Use

• Hospital
• Medical cente

By Region

• North America (Country Analysis: The USA, Canada, and Mexico),
• Europe (Country Analysis: Germany, France, The UK, Russia, and the Rest of Europe),
• Asia-Pacific (Country Analysis: China, India, Australia, South Korea, and the Rest of Asia-Pacific),
• Rest of the World (Country Analysis: Saudi Arabia, Brazil, and Others).

Key Players

Some of the key players operating in the brain tumor diagnosis and treatments market are-

• AstraZeneca (UK)
• Carestream Health (US)
• GE Healthcare
• Hitachi (Japan)
• Merck (Germany)
• Philips Healthcare (Netherlands)
• Pfizer
• Shimadzu (Japan)
• Siemens Healthineers (Germany)
• Canon Medical Systems (Japan)

Report Features

This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.
What Deliverables Will You Get in this Report

Target Audience

Here is the list of the group of customers that the brain tumor diagnosis and treatments market hopes to have the greatest opportunity to convert-

• Companies
• Distributors
• Medical companies
• Government organization

Research Methodology

This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools.

More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles have been leveraged to gather the data.

We conducted more than 10 detailed primary interviews with the market players across the value chain in all four regions and with industry experts to obtain both qualitative and quantitative insights.

Customization Option

Stratview Research offers one of the following free customization options to our respectable clients:

Company Profiling

• Detailed profiling of additional market players (up to three players)
• SWOT analysis of key players (up to three players)

Competitive Benchmarking

Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances

Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com.